91 abstracts found.



Results filter

Heterogeneity, drug resistance and clonal evolution of colorectal cancers

Year:

Session type: ,

Alberto Bardelli1

1University of Toringo, Turin, Italy

Epigenetic Targets in Cancer

Year:

Session type: ,

Kristian Helin1

1University of Copenhagen, Copenhagen, Denmark

T Cell Engineering as Therapy for Cancer and HIV: Our Synthetic Future

Year:

Session type: ,

Carl June1

1University of Pennsylvania, Philadelphia, PA, USA

Evolutionary tales in leukaemia

Year:

Session type: ,

Mel Greaves1

1The Institute of Cancer Research, Sutton, UK

Probing the transcriptional consequences of Ras and Rho activation

Year:

Session type: ,

Richard Treisman1,2

1Cancer Research UK London Research Institute, London, UK,2Francis Crick Institute, London, UK

Is late diagnosis of cancer real and if so what can we do about it?”

Year:

Session type: ,

Harpal Kumar1

1Cancer Research UK, London, UK

“Rethinking” Cancer as a Complex Adaptive System”

Year:

Session type: ,

Anna Barker1

1Complex Adaptive Systems Institute, Arizona, USA

Genomic tests to personalized therapy of patients with metastatic breast cancer

Year:

Session type: ,

fabrice andre1

1gustave roussy, villjuif, France

Hormone Therapy for Prostate Cancer

Year:

Session type: ,

Charles Sawyers1

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Big data and patient reported outcome measures (PROMs)

Year:

Session type: ,

Amy Abernethy1

1Flatiron Health, New York, NY, USA

Technological Developments in Radiotherapy

Year:

Session type: ,

Uwe Oelfke1

1Institute of Cancer Research, Sutton, Surrey, UK

Cancer survivorship: Surveying the landscape of cancer survivorship research

Year:

Session type:

Eva Grunfeld1
1University of Toronto, Toronto, Canada

Lgr5 stem cells in self-renewal and cancer

Year:

Session type:

Hans Clevers1
1Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences & University Medical Centre Utrecht, Utrecht, The Netherlands

Chemoprevention: Why do we keep getting it wrong?

Year:

Session type:

John Potter1
1University of Washington, Seattle, USA, 2Massey University, Wellington, New Zealand

Modelling drug sensitivity and resistance in tumour-derived cell lines

Year:

Session type:

Jeff Settleman1
1Genentech, South San Francisco, USA

Improving cancer survival in England:  Driving for the best

Year:

Session type:

Sir Mike Richards1
1National Clinical Director for Cancer and End of Life Care, England, UK

Genome stability: From worms to human disease

Year:

Session type:

Simon Boulton1
1Cancer Research UK, London Research Institute, South Mimms, UK

TOR signalling and the control of cell growth

Year:

Session type:

Michael N. Hall1
1Biozentrum, University of Basel, Basel, Switzerland

Cancer care in 2011 is disease based, not discipline based

Year:

Session type:

Murray Brennan1
1Memorial Sloan-Kettering Cancer Center, New York, USA

Evolution of the cancer genome

Year:

Session type:

Michael R. Stratton1
1Wellcome Trust Sanger Institute, Cambridge, UK

Stratified medicine in colorectal cancer: Current state and challenges ahead

Year:

Session type:

Sabine Tejpar1
1Digestive Oncology and Center for Human Genetics, University Hospital Leuven, Leuven, Belgium

Aberrant cell signalling in cancer

Year:

Session type:

Chris Marshall1
1Institute of Cancer Research, London, UK

Functional genomics, experimental models and cancer

Year:

Session type:

William Hahn
Dana-Farber Cancer Institute, Boston, USA

Cancer pain control

Year:

Session type:

Eduardo Bruera
The University of Texas MD Anderson Cancer Center, USA

Targeting the CRKL/Src Family Kinases in Rhabdomyosarcoma

Year:

Session type:

Lee Helman
National Cancer Institute, Bethesda, USA

The breast screening review

Year:

Session type:

Harpal Kumar
Cancer Research UK, London, UK

Personalized Genomic Approaches and Pathway Identification for Individualized Prostate Cancer Therapy

Year:

Session type:

Robert Bristow
Ontario Cancer Institute/Princess Margaret Cancer Center & University of Toronto, Canada

The Breast Screening Review: evidence and recommendations

Year:

Session type:

Sir Michael Marmot
Institute of Health Equity, University College London, UK

Clinical cancer genetics in the era of personalised cancer medicine

Year:

Session type:

Judy E. Garber
Dana-Farber Cancer Institute, Boston, USA

Targeting myeloma cells and their microenvironment

Year:

Session type:

Kenneth C. Anderson
Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA

Cancer Research UK Lifetime Achievement in Cancer Research Prize Winner Drugging the undruggable: How to finally tackle Myc, Ras, and p53

Year:

Session type:

David Lane
Agency for Science, Technology and Research, Singapore

Title TBC

Year:

Session type:

Neal Rosen
Memorial Sloan-Kettering Cancer Center, New York, USA

Metastasis seeds and niches

Year:

Session type:

Joan Massagué
Memorial Sloan-Kettering Cancer Center, New York, USA

The application of translational science in non-small cell lung cancer (NSCLC): Successes, failures and pitfalls

Year:

Session type:

Frances A Shepherd1
1Princess Margaret Hospital and University of Toronto, Toronto, Canada

Cervical cancer – problem solved?

Year:

Session type:

Peter Sasieni1
1Wolfson Institute of Preventive Medicine, Queen Mary University, London, London, UK

The biology and clinical exploitation of BRAF and RAS signalling in cancer

Year:

Session type:

Richard Marais1
1The Cancer Reserch UK Manchester Institute, Manchester, UK

Chromosomal instability and hopeful monsters: A driving force for cancer heterogeneity and evolution

Year:

Session type:

Charles Swanton1
1Cancer Research UK London Research Institute and University College London Cancer Institute, London, UK

Inflammation and cancer: Reprogramming the immune microenvironment as an anti-cancer therapeutic strategy

Year:

Session type:

Lisa M Coussens1
1Knight Cancer Institute, Oregon Health & Sciences University, Portland, USA

Cancer Research UK Lifetime Achievement Award winner: Polygenic susceptibility: What might it tell us?

Year:

Session type:

Bruce Ponder1
1Cancer Research UK Cambridge Institute, Cambridge, UK

Defective DNA strand break repair, genome instability and cancer

Year:

Session type:

Stephen C West1
1Cancer Research UK London Research Institute, South Mimms, UK

Improving value in cancer care: The case for palliative medicine

Year:

Session type:

R Sean Morrison1
1Hertzberg Palliative Care Institute, National Palliative Care Research Center, and Mount Sinai Medical Center, New York, USA

Cancer predisposition genes: Past glories, future imperatives

Year:

Session type:

Nazneen Rahman1
1The Institute of Cancer Research and The Royal Marsden Hospital Foundation Trust, London, UK

Whither localised therapies

Year:

Session type:

Tim Maughan1
1Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Oxford, UK

Cancer genomics: state of the science and clinical translation

Year:

Session type:

Elaine R Mardis1
1The Genome Institute at Washington University School of Medicine, St Louis, USA

From symptom to cancer treatment: the vital clinical and political leadership

Year:

Session type:

Peter Vedsted1
1Aarhus University, Aarhus, Denmark

BACR Tom Connors lecture – Targeting and imaging cancer phenotypes: Focal Adhesion Kinase as a critical regulator of tumour cells and the host immune response

Year:

Session type:

Margaret Frame1
1Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK

Whither metabolomics

Year:

Session type:

Karen H Vousden1
1Cancer Research UK Beatson Institute, Glasgow, UK

Targeting phosphoinositide 3-kinase for cancer therapy

Year:

Session type:

Lewis C Cantley1
1Weill Cornell Medical School, Cornell University, New York, USA

Targeting phosphoinositide 3-kinase for cancer therapy

Year:

Session type:

Lewis C Cantley1
1Weill Cornell Medical School, Cornell University, New York, USA

Communicating risk and uncertainty to patients and the media

Year:

Session type:

David Spieglehalter1
1University of Cambridge, Cambridge, UK